X-37, a South San Francisco, CA-based artificial intelligence-enabled drug discovery company, closed a $14.5m Series A financing.
The round was led by DCVC Bio with participation from Alpha Intelligence Capital and Hemi Ventures. Following the financing, Kiersten Stead and Antoine Blondeau of Alpha Intelligence Capital joined the Board of Directors of X-37.
The company intends to use the funds to expand the number of drug development programs at X-37 and to advance identified drug leads through laboratory and preclinical testing, with the goal of beginning human clinical trials by 2022.
Led by David Collier, M.D., CEO, and a team of pharmaceutical developers from Velocity Pharmaceutical Development, X-37 is a pharmaceutical discovery and development company, which uses advanced artificial intelligence technology from Atomwise, Inc., to screen vast libraries of chemical compounds against high value pharmaceutical targets. The company develops these novel drug candidates under an innovative LLC structure which allows the sale or partnership of individual development programs in an efficient manner.
X-37’s development programs include ZAP-70 for autoimmune disease, PIM3 and SHP2 for cancer, and Factor XIIa for anticoagulation.
The founding leadership team of the company is comprised of:
– David Collier, M.D.,
– Matthew Kerby, Ph.D., PE,
– James Larrick, M.D., Ph.D.,
– Andrew Perlman, M.D., Ph.D.,
– Anie Roche, J.D., Ph.D., and
– Ed Schnipper, M.D.